File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: SARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection

TitleSARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection
Authors
Issue Date2010
PublisherPortland Press Ltd.. The Journal's web site is located at http://www.cellbiolint.org/cbi/default.htm
Citation
The 8th International Symposium on Frontiers in Life Sciences, YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62 How to Cite?
AbstractWe have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.
DescriptionConference Theme: New Advances and Challenges in Multidisciplinary Research
主題: 多學科交叉研究的新進展與挑戰
Persistent Identifierhttp://hdl.handle.net/10722/135932
ISSN
2023 Impact Factor: 3.3
2023 SCImago Journal Rankings: 0.847

 

DC FieldValueLanguage
dc.contributor.authorZheng, Ben_US
dc.contributor.authorDu, Len_US
dc.contributor.authorZhao, Gen_US
dc.contributor.authorLin, Yen_US
dc.contributor.authorSui, Hen_US
dc.contributor.authorChan, CSen_US
dc.contributor.authorHe, Yen_US
dc.contributor.authorJiang, Sen_US
dc.contributor.authorZhou, Yen_US
dc.contributor.authorYuen, KYen_US
dc.date.accessioned2011-07-27T02:00:05Z-
dc.date.available2011-07-27T02:00:05Z-
dc.date.issued2010en_US
dc.identifier.citationThe 8th International Symposium on Frontiers in Life Sciences, YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62zh_HK
dc.identifier.issn1065-6995-
dc.identifier.urihttp://hdl.handle.net/10722/135932-
dc.descriptionConference Theme: New Advances and Challenges in Multidisciplinary Research-
dc.description主題: 多學科交叉研究的新進展與挑戰zh_HK
dc.description.abstractWe have previously reported that a subunit protein vaccine based on receptor binding domain (RBD) of SARS-CoV S protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing antibody (NA) responses in immunized animals. In this study, systemic, mucosal and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the intramuscular (i.m.) and intranasal (i.n.) routes of administration. Our results demonstrated that: (1) the i.n. vaccination induced systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but local humoral immune response was much stronger; (2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-c producing CD3+/CD8+ T cells in both lungs and spleen; (3) the i.n. vaccination induced a similar protection as the i.m. vaccination against SARS-CoV challenge in mice; (4) higher titers of mucosal IgA and serum NA were associated with lower viral load and less pulmonary pathological damage, while no antibody-mediated disease enhancement effect was observed; and (5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.-
dc.languageengen_US
dc.publisherPortland Press Ltd.. The Journal's web site is located at http://www.cellbiolint.org/cbi/default.htm-
dc.relation.ispartofCell Biology International-
dc.relation.ispartof2010生命科學前沿國際研討會-
dc.rightsThe final version of record is available at http://www.cellbiolint.org/cbi/default.htm-
dc.titleSARS-CoV S protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infectionen_US
dc.typeConference_Paperen_US
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_US
dc.identifier.emailZhao, G: zhaogy@hkucc.hku.hken_US
dc.identifier.emailChan, CS: cschan@hku.hken_US
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityZheng, B=rp00353en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros188731en_US
dc.identifier.volume34-
dc.identifier.issue8-
dc.identifier.spageS62-
dc.identifier.epageS62-
dc.publisher.placeUnited Kingdom-
dc.description.otherThe 8th International Symposium on Frontiers in Life Sciences (生命科學前沿國際研討會 2010), YinChuan, China, 25-28 August 2010. In Cell Biology International, 2010, v. 34 n. 8, p. S62zh_HK
dc.identifier.issnl1065-6995-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats